RA0165

antibody from Oursmab

Targeting: CTLA4 CD, CD152, CELIAC3, CTLA-4, GSE, IDDM12

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0165

Provider

Oursmab

Product name

Evalstotug (Biosimilar Reference Antibody) (CTLA4)

Antibody type

Monoclonal

Description

Evalstotug (development code BA3071) is an investigational, conditionally active biologic (CAB) monoclonal antibody being developed for cancer immunotherapy. It is designed as a novel anti-CTLA-4 therapy with an integrated safety switch. Unlike traditional CTLA-4 inhibitors (e.g., ipilimumab), which are constitutively active and can cause significant systemic immune-related adverse events (irAEs), evalstotug is engineered to be active only within the acidic tumor microenvironment (TME). At the near-neutral pH of healthy tissues, it remains in a mostly inactive state with minimal target binding. However, in the acidic conditions often found in tumors, the antibody undergoes a conformational change, exposing its active binding site and allowing it to potently block the CTLA-4 pathway locally. This design aims to concentrate the immune-stimulating effects at the tumor site while sparing healthy tissues, thereby improving the therapeutic index.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.